Asset Details
Do you wish to reserve the book?
Intraductal chemotherapy for triple-negative breast cancer: a pathway to minimally invasive clinical treatment
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Intraductal chemotherapy for triple-negative breast cancer: a pathway to minimally invasive clinical treatment
Do you wish to request the book?
Intraductal chemotherapy for triple-negative breast cancer: a pathway to minimally invasive clinical treatment
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Intraductal chemotherapy for triple-negative breast cancer: a pathway to minimally invasive clinical treatment
2025
Overview
Triple-negative breast cancer (TNBC) is traditionally treated with systemic chemotherapy, often resulting in significant off-target toxicity. In this study, we assess the efficacy of intraductal chemotherapeutic delivery, aimed at reducing systemic side effects. Using an in situ TNBC model, created by intraductal injection of 4T1-luc cells, we identified day 3 post-tumor implantation as an optimal early intervention point. Echocardiographic analysis confirmed that intraductal administration of eribulin (ERI) or doxorubicin (DOX) did not cause cardiac dysfunction or apoptosis. Our results demonstrate that intraductal delivery of ERI and DOX significantly enhances anti-tumor and anti-metastatic effects. Mechanistically, ERI followed by DOX increased intratumoral perfusion, improved drug concentration, reversed epithelial-mesenchymal transition, and inhibited tumor cell invasion and metastasis. Additionally, this approach triggered immunogenic cell death and activated a systemic anti-tumor immune response. These findings underscore the potential of intraductal chemotherapy as a safe, highly effective approach, offering a preclinical foundation for minimally invasive TNBC therapies.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Antibiotics, Antineoplastic - administration & dosage
/ Antibiotics, Antineoplastic - therapeutic use
/ Biomedical and Life Sciences
/ Cancer
/ Doxorubicin - administration & dosage
/ Doxorubicin - therapeutic use
/ Epithelial-mesenchymal transition
/ Furans - administration & dosage
/ Health Promotion and Disease Prevention
/ Ketones - administration & dosage
/ Lung Neoplasms - prevention & control
/ Methods
/ Mice
/ Minimally invasive treatment
/ Neoplasm Metastasis - prevention & control
/ Oncology
/ Polyether Polyketides - administration & dosage
/ Polyether Polyketides - therapeutic use
/ Proteins
/ Software
/ Toxicity
/ Triple Negative Breast Neoplasms - drug therapy
/ Triple-negative breast cancer
/ Tumors
